How CurifyLabs is Powering the Future of Personalized Medicine

CurifyLabs, powering a new generation of personalized therapies, led by Charlotta Topelius, Niklas Sandler, and the team, has announced the closing of a $14 million Series A funding round. The round was co-led by Sandwater and HealthCap, with participation from Tesi (Finnish Industry Investment Ltd.) and existing investors, including Lifeline Ventures. US customers and employees also participated in the round.

The funding will support CurifyLabs' expansion in the U.S., strengthen its supply chain, enhance customer support, and accelerate product innovation.

CurifyLabs' Compounding System Solution (CSS) combines proprietary software, GMP-manufactured excipient bases, and 3D printing technology to automate the production of personalized medications with greater speed and precision than traditional pharmacy compounding. The platform is already used by pharmacies in 21 U.S. states and across Europe to prepare thousands of doses daily.

According to Sandwater, personalized medicine is becoming an increasingly important part of healthcare, and CurifyLabs is well positioned to help pharmacies deliver customized treatments more safely and efficiently. The firm believes the company's technology combines clinical rigor with operational efficiency, supporting its expansion across the U.S. and international markets.

Investors highlighted CurifyLabs' combination of scientific expertise, strong execution, and growing international momentum. They pointed to the company's expanding presence in the U.S. as evidence of its ability to bring advanced pharmacy technology to global markets.

According to CEO Charlotta Topelius, the funding will enable CurifyLabs to further strengthen its clinical standards, product quality, and customer support as the company enters its next phase of growth.

The funding will accelerate development of the CurifyLabs platform, including the PharmaPrinter Aurum, which compounds medications up to nine times faster than manual methods. The platform is ISO 13485 certified and designed to comply with FDA 503A/503B standards for non-sterile compounding.